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Abstract
Chikungunya virus (CHIKV) is a re-emerging mosquito borne alphavirus that has caused large scale epidemics in the
countries around the Indian Ocean, as well as leading to autochthonous transmission in some European countries. The
transmission of the disease has been driven by the emergence of an African lineage of CHIKV with enhanced transmission
and dissemination in Aedes mosquito hosts. Two main genotypes of this lineage have been circulating, characterized by the
presence of a substitution of a valine for an alanine at position 226 of the E1 protein. The outbreak, numbering in millions of
cases in the infected areas, has been associated with increasing numbers of cases with non-classical presentation including
encephalitis and meningitis. This study sought to compare the original Ross strain with two isolates from the recent
outbreak of chikungunya fever in respect of infectivity and the induction of apoptosis in eight mammalian cell lines and two
insect cell lines, in addition to generating a comprehensive virus production profile for one of the newer isolates. Results
showed that in mammalian cells there were few differences in either tropism or pathogenicity as assessed by induction of
apoptosis with the exception of Hela cells were the recent valine isolate showed less infectivity. The Aedes albopictus C6/36
cell line was however significantly more permissive for both of the more recent isolates than the Ross strain. The results
suggest that the increased infectivity seen in insect cells derives from an evolution of the CHIKV genome not solely
associated with the E1:226 substitution.
Citation: Wikan N, Sakoonwatanyoo P, Ubol S, Yoksan S, Smith DR (2012) Chikungunya Virus Infection of Cell Lines: Analysis of the East, Central and South African
Lineage. PLoS ONE 7(1): e31102. doi:10.1371/journal.pone.0031102
Editor: Lisa Ng Fong Poh, Agency for Science, Technology and Research - Singapore Immunology Network, Singapore
Received August 31, 2011; Accepted January 2, 2012; Published January 27, 2012
Copyright:  2012 Wikan et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by grants from the Office of the Higher Education Commission and Mahidol University under the National Research
Universities Initiative and Mahidol University. N.W. is supported by a TRF and Mahidol University (Thai Royal Golden Jubilee) Scholarship. The funders had no role
in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: duncan_r_smith@hotmail.com
Introduction
Chikungunya fever is a mosquito transmitted viral disease that is
classically characterized by fever, rash and a severe, often
persistent, joint pain (arthralgia) and while rarely fatal, widespread
outbreaks of chikungunya fever have led to significant long term
morbidity and economic loss [1,2,3]. Chikungunya fever was first
formally described in 1955 following an outbreak of the disease in
southern Tanzania in 1952 [4] and the disease occurs in Africa,
the Indian subcontinent and Southeast Asia [5]. The severe
arthralgia can serve to discriminate the disease from the largely
similar dengue fever [6] and while the pain is normally resolved in
a few days or weeks, prolonged joint pain can persist for several
months or even years [7,8]. In the last few decades, there have
been an increasing number of reports of severe complications of
chikungunya fever. In the 1963 outbreak in India, neurological
and haematological complications were reported for the first time
[9,10] and recent outbreaks of the disease have been associated
with periventricular encephalitis and meningoencephalitis in
neonates [11,12] as well as renal and hepatic dysfunction [13]
ophthalmic involvement, hypokalemic paralysis, hearing loss,
Guillain Barre Syndrome and acute flaccid paralysis
[14,15,16,17,18,19,20,21] and occasional deaths have been
reported [22,23,24,25]. More recently, neurologic involvement
has been reported in Thailand [26], while deaths as a result of
chikungunya infection have been reported in Malaysia [24,27].
The causative agent of chikungunya fever, the Chikungunya
virus (CHIKV), is an Alphavirus belonging to the family Togaviridae
and was originally isolated from the southern Tanzanian outbreak
in 1952 [28]. The genome consists of a positive sense single
stranded RNA molecule of approximately 11.8 kb which has both
a5 9-methylguanylate cap and a 39-polyadenylate tail [29] and
encodes for four non-structural proteins (nsP1 to nsP4), three
structural proteins (C, E1 and E2) and two small peptides (E3 and
6 K) in two open reading frames [29,30].
Sequence analysis of genomes isolated from different geographic
areas has shown that there are three distinct clades of CHIKV,
which are the so called West African, East, Central and South
African (ECSA) and Asian lineages, with Asian lineage arising
from the ECSA lineage some 50 to 300 years ago [31,32]. In
Africa, CHIKV is believed to be maintained in a primarily sylvatic
cycle involving wild, non human primates and forest dwelling Aedes
mosquitoes such as Aedes furcifer and Aedes taylori, while in Asia the
virus is believed to be transmitted primarily in a mosquito-human-
mosquito cycle during epidemics with the urban Aedes aegypti being
the primary transmission vector [13,33].
In 2005/2006 significant attention was focused on CHIKV as a
consequence of a massive outbreak of chikungunya fever on the
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nearly 40% of the population [34]. Subsequent outbreaks of
chikungunya fever in India, Sri Lanka, Malaysia, Singapore and
Thailand in the following years resulted in millions of infected
patients and the large numbers of patients coupled with the
absence of a vaccine and lack of a specific treatment made
chikungunya fever a significant worldwide public health
problem [33,35,36]. Sequence analysis showed that the CHIKV
r e s p o n s i b l ef o rt h eo u t b r e a kb e l o n g e dt ot h eE C S Ac l a d eo f
CHIKV [37,38,39,40,41]. More importantly, much of the
outbreak was being driven by adaptation of the virus to Aedes
albopictus mosquitoes as opposed to the classical vector of Aedes
aegypti and the adaptation of the virus to Aedes albopictus was
coupled with the emergence of CHIKV bearing a hallmark
substitution in the E1 protein at position 226 [40]. This change,
the substitution of a valine for an alanine (E1: A226V) increased
the transmissibility and dissemination of the virus in Aedes
albopictus as well as possibly in Aedes aegypti mosquitoes [42].
Surprisingly, evidence suggests that this substitution has arisen
independently at least three times during the last few years in
what is believed to be a rare example of convergent evolution
[33,38,43]. While the mechanism by which this substitution
increases the fitness of the virus in Aedes albopictus mosquitoes
remains poorly understood [42,44], the consequences are
significant. An autochthonous outbreak of chikungunya fever
in Italy in 2007 resulted from convergence of high levels of Aedes
albopictus in Italy at the time of a visit of an asymptomatic
CHIKV infected person [45,46], raising the possibility of much
wider dissemination of CHIKV as a result of its adaptation to
the Aedes albopictus mosquito [47].
At this point there is little evidence how or if the E1: A226V
substitution alters the interaction with mammalian cells or whether
the currently circulating ECSA lineages (E1: A226 or E1: 226V)
differ significantly from the original ECSA lineage isolated in
Africa in the early 1950 s. To start to address this question, we
examined the ability of three ECSA lineages to infect a number of
mammalian and insect cell lines (both Aedes aegypti and Aedes
albopictus), and determined the consequences of infection by
determining whether apoptosis was induced. Two of the CHIKVs
were recent isolates, while the third CHIKV was the prototype
Ross strain.
The tissue tropism of CHIKV in humans remains to be fully
defined, but previous studies have shown that a number of cell
types including epithelial, endothelial and fibroblast cells are all
susceptible to infection [25]. Monocyte derived macrophages are
susceptible to infection and are believed to play a critical role in
the disease pathology [48], while monocytes and monocytic cells
lines are variably susceptible [25,49]. Consistent with the reports
of neurological involvement, both neurons and glial cells are
believed to be susceptible to infection [11]. In a non-human
primate model, persistent infection of liver tissues, as well as
significant levels of hepatocyte cell death implicates the
involvement of hepatocytes in the disease [48]. We therefore
selected a range of cell lines including CHME-5 (human
embryonic fetal microglial), HEK293T/17 (human embryonic
kidney), HepG2 (human hepatocarcinoma), MRC-5 (human lung
fibroblast), Hela (human cervical epithelial), SW-982 (human
synovial sarcoma), U937 (human histiocytic lymphoma) and Vero
(African Green Monkey Kidney) cells and assessed these cells for
infection and induction of apoptosis in response to infection. In
mammalian cells surprisingly few differences were found between
the different isolates while insect cells showed the largest
difference between Ross strain and the later isolates in C6/36
Aedes albopictus cells.
Results
Three ECSA CHIKV isolates were used in this study. The first
was an ECSA E1: 226 V isolate obtained from a patient in
Thailand in 2009 and passaged twice in Aedes albopictus C6/36 cells
before further passage in Vero cells. The second was an ECSA E1:
A226 isolate (a kind gift of the Emerging Infectious Disease
Program, Duke-NUS Medical School, Singapore) which was
initially passaged in BHK-21 and twice further in Vero. The third
isolate was ECSA Ross strain, which was passaged 5 times through
Vero (and which is also E1: A226). The identity of all isolates was
confirmed by DNA sequencing (data not shown). Virus titer for
each isolate was determined by standard plaque assay on Vero
cells. For the ECSA E1: 226 V isolate, virus production from 8
mammalian cell lines (CHME-5, HEK293T/17, HepG2, MRC-5,
Hela, SW-982, U937 and Vero) and 2 insect cell lines, the Aedes
albopictus derived C6/36 cell line [50] and the Aedes aegypti derived
CCL-125 cell line [50] was determined by standard plaque assay
on Vero cells after infection at a multiplicity of infection (m.o.i.) of
1. All three isolates were then used to infect the same 10 cell lines
at a multiplicity of infection (m.o.i.) of 1 and the susceptibility of
each cell line to the virus was quantified by flow cytometry using
an anti-alphavirus monoclonal antibody in parallel with determi-
nation of the induction of apoptosis also by flow cytometry after
staining cells with FITC-conjugated Annexin V and propidium
iodide. All experiments were undertaken independently in
triplicate. For selected cell lines immunocytochemistry was used
to directly visualize infection.
The ECSA E1: 226 V isolate
We initially determined the profile of virus productivity for the
ECSA E1: 226 V isolate after infection of CHME-5, HEK293T/
17, HepG2, MRC-5, Hela, SW-982, U937, Vero and C6/36. Titer
of virus inthe supernatant was determinedby standard plaqueassay
immediately upon addition of the virus to the cells at m.o.i. 1 (22
h.p.i.) and at 4, 8 and 12 h.p.i. as well as on 1, 3 and 5 days p.i.
(d.p.i.). Some cell lines also included a 0 hour and a 2 d.p.i. time
point. Each experiment was undertaken independently in triplicate.
Results of the plaque assays for CHME-5 (Figure 1A), HepG2
(Figure S1A) Hela (Figure S2A) HEK293T (Figure S3A), Vero
(Figure S4A), SW-982 (Figure S5A), MRC-5 (Figure S6A) and
C6/36 (Figure 2A) showed that in the first 12 h post infection
there was a decrease of virus levels in the medium, corresponding
to virus binding and/or internalization, but by 1 d.p.i. (C6/36,
Vero and MRC-5), 2 d.p.i. (HEK293T/17) or 3 d.p.i. (Hela,
CHME-5 and HepG2) de novo virus production over the level of
input virus had clearly occurred after which titer generally started
to decline. SW-982 (Figure S5A) showed a characteristic drop in
virus titer following the infection period however there was only a
slight increase in virus titer on day 2 p.i. which did not reach input
levels, followed by a rapid decline of titer on days 3 to 5 p.i. U937
infections showed no decrease of virus titer in the first 12 hours
p.i., and the titer declined over the next 5 days to 2Log lower than
the input level (Figure S7A).
A detailed profile of susceptibility to infection and the induction of
apoptosis were determined for the ECSA E1: 226 V isolate for each
of the cell lines. Cells were either mock infected or infected with
CHIKV ECSA E1: 226 V at m.o.i. 1 and cells were subsequently
analyzed on days 1, 2, 3 and 5 p.i. by flow cytometry after staining
with either an anti-alphavirus monoclonal antibody followed by an
appropriate FITC-labeled secondary antibody or with FITC-
conjugated Annexin V and propidium iodide. Each experiment
was undertaken independently in triplicate. Results for infection and
apoptosis for all cell lines are summarized in Figure 3 and Table 1.
The Chikungunya Virus ECSA Lineage
PLoS ONE | www.plosone.org 2 January 2012 | Volume 7 | Issue 1 | e31102Figure 1. CHIKV infection of CHME-5 human microglial cells. A. CHME-5 cells were mock infected (M) or infected with CHIKV ECSA E1: 226 V
(EV) at m.o.i. of 1. Infected cells and culture medium were collected daily and the medium assayed for levels of infectious CHIKV at the times indicated
by standard plaque assay on Vero cells, while cells were assayed for infectivity and induction of apoptosis by flow cytometry after staining with an
anti-alphavirus monoclonal antibody and FITC-conjugated Annexin V/propidium iodide respectively. B. CHME-5 cells were mock infected (M) or
infected with ECSA CHIKV E1: A226 (EA), ECSA CHIKV E1: 226 V (EV) or Ross strain (RO) at m.o.i. of 1 and assayed for infectivity and induction of
apoptosis by flow cytometry on the days indicated. All experiments were undertaken independently in triplicate with duplicate analysis of virus titers.
Error bars show S.D. C to F. CHME-5 cells were mock infected (C) or infected with ECSA CHIKV E1: 226 V (D), ECSA CHIKV E1: A226 (E) or Ross strain (F)
and on day 2 p.i. stained with a mouse anti-alphavirus monoclonal antibody followed by a FITC conjugated goat anti-mouse IgG polyclonal antibody
(green). Nuclei of cells were stained with TO-PRO-3 iodide (red). Non-contrast adjusted merged images are shown.
doi:10.1371/journal.pone.0031102.g001
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S1A), Vero (Figure S4A) and MRC-5 (Figure S6A) showed both
infection and apoptosis rates of over 80% by 5 d.p.i. To directly
visualize infection, Vero cells were either mock infected or infected
with CHIKV E1: 226 V, and on days 1 and 2 p.i. stained with a
primary anti-alphavirus monoclonal antibody followed by an
appropriate FITC-conjugated secondary antibody as well as with
TO-PRO-3 iodide to visualize nuclei before examination under a
confocal microscope. Results (Figure S4C to F) confirmed high
levels of infection of Vero on day 1 post infection (Figure S4A and
Table 1) and by day 2 p.i. characteristic cellular blebs which
stained positive for CHIKV were observed (Figure S4F) as
previously seen by others [51].
Two further cell lines, CHME-5 (Figure 1A) and HEK293T/17
(Figure S3A) showed infection rates of over 80% by 5 d.p.i. but
levels of apoptosis of approximately 60%. Hela infection levels
reached a maximum of only some 30% of cells by day 5 p.i. and
levels of induced apoptosis only reached about 25% on day 5 p.i.
(Figure S2A and Table 1). Both SW-982 (Figure S5A) and U937
(Figure S7A) cells showed no appreciable levels of either infection
or apoptosis. In contrast, C6/36 cells showed high levels of
infection (.80%) from 1 d.p.i. but this level decreased dramat-
ically to approximately 20% by 5 d.p.i. and occurred without the
significant induction of apoptosis (Figure 2A).
Comparison of ECSA E1: 226 V, ECSA E1:A226 and Ross
strain
CHME-5, HEK293T/17, HepG2, Hela, SW-982, U937, Vero,
C6/36 and CCL-125 cells were either mock infected or infected
separately with CHIKV ECSA E1: A226, ECSA E1: 226 V and
Ross strain, and the cell susceptibility and induction of apoptosis
examined on days 1 and 5 p.i. Because of technical difficulties with
the MRC-5 cell line (the cells lost viability after the 5
th passage in
our hands, and so only limited expansion was possible) this cell line
was not included in the comparative analysis. Evaluation of
susceptibility of U937 cells to all three CHIKV isolates showed no
apparent infection of these cells with any isolate (Figure S7B and
Table 1). In light of the negative result for infection, induction of
apoptosis was not formally evaluated. Summarized results for all
cell lines analyzed are shown in Figure 4.
CHME-5 (Figure 1B), HepG2 (Figure S1B), HEK293T/17
(Figure S3B) and Vero (Figure S4B) all showed comparable rates
of infection and apoptosis in response to infection with all three
isolates, although CHME-5 (Figure 1B) showed a much lower rate
of infection on 1 d.p.i. with E1: 226 V as compared to the other
two isolates (see also Figure 4 and Table 1). To directly visualize
infection, CHME-5 cells were either mock infected or infected
separately with all three CHIKV isolates, and on day 2 p.i. stained
with a primary anti-alphavirus monoclonal antibodies followed by
an appropriate FITC-conjugated secondary antibody as well as
with TO-PRO-3 iodide to visualize nuclei before examination
under a confocal microscope. Results (Figure 1C to F) confirmed
high levels of infection with all three CHIKV isolates.
The E1: 226 V isolate showed lower rates of both infection and
apoptosis of Hela cells as compared to the E1: A226 and Ross
strain isolates (Figure S2B), while for the cell line SW-982 highest
levels of infection were seen with Ross strain (Figure S5B and
Table 1) although this reached a maximum of only 20%. Similarly,
only a slight (maximum 20%) induction of apoptosis was observed
(Figure S5B and Table 1). The low levels of infection were
Figure 2. CHIKV infection of C6/36 Aedes albopictus cells. A. C6/36 cells were mock infected (M) or infected with CHIKV ECSA E1: 226 V (EV) at
m.o.i. of 1. Infected cells and culture medium were collected daily and the medium assayed for levels of infectious CHIKV at the times indicated by
standard plaque assay on Vero cells, while cells were assayed for infectivity and induction of apoptosis by flow cytometry after staining with an anti-
alphavirus monoclonal antibody and FITC-conjugated Annexin V/propidium iodide respectively. B. C6/36 cells were mock infected (M) or infected
with ECSA CHIKV E1: A226 (EA), ECSA CHIKV E1: 226 V (EV) or Ross strain (RO) at m.o.i. of 1 and assayed for infectivity and induction of apoptosis by
flow cytometry on the days indicated. All experiments were undertaken independently in triplicate with duplicate analysis of virus titers. Error bars
show S.D.
doi:10.1371/journal.pone.0031102.g002
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antibody. Results showed only scattered infected cells for all three
isolates on day 5 p.i. (Figure S5C to F).
Independent analysis of infection of C6/36 cells with all three
CHIKV isolates is shown in Figure 2B and Table 1. Again, high
levels of infection were seen on day 1 p.i. for CHIKV E1: A226
and CHIKV E1: 226 V which declined less than 20% on day 5
p.i. Ross strain however showed minimal infection of C6/36 cells
on day 1, and a slight increase in infection by day 5 p.i.
(Figures 2B). In all cases the number of apoptotic cells was
comparable with mock infected cells.
To confirm this result, cells were infected with all three CHIKV
isolates separately and examined by immunocytochemistry on days
1,3 and 5p.i.inparallelwithmockinfected cells.Results(Figure S8)
showed high levels of CHIKV positive cells for CHIKV E1: A226
and CHIKV E1: 226 V on day 1 p.i. and only scattered minimally
positive single cells by day 5 p.i. Ross strain showed significantly
fewer infected cells on day 1 p.i. but more infected cells on day 3 p.i.
as compared to the other two CHIKV isolates, however by day 5
p.i. there were also few positive cells (Figure S8).
The Aedes aegypti cell line CCL-125 was examined for infectivity
with all three CHIKV isolate. As shown in Figure S9, while there
were some infected cells on day 1 p.i. (approximately 20%) for the
CHIKV E1: 226 V isolate, this declined over the following days.
Infection of CCL-125 cells with the CHIKV E1: A226 isolate
showed approximately 10% infection on day 1 which also declined
over the following days. Surprisingly, no detectable infection of
CCL-125cellswasseenwiththeRossstrain(FigureS9andTable1).
Discussion
CHIKV has been present in Africa, Indian and many parts of
Southeast Asia for many years [32,33]. In Southeast Asia for
Figure 3. Infection and apoptosis in response to CHIKV E1:226 V infection. Summary of percentage infection (A) and apoptosis induction
(B) in cell lines infected with CHIKV ECSA E1: 226 V (226 V) or mock infected (Mock).
doi:10.1371/journal.pone.0031102.g003
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relatively limited, small scale outbreaks [33,52] although there was
immunological evidence for exposure of local populations to the
virus [53,54]. However, the sudden and unpredicted outbreak of
CHIKV that swept out of Africa and caused large epidemics in
islands in the Indian Ocean and in the countries around the rim of
the Indian Ocean served to refocus attention on this virus
[34,36,55].
Epidemiological evidence showed that the massive outbreak has
its roots in an outbreak of chikungunya fever in Kenya in 2004,
and that outbreaks in India and Southeast Asia were driven by
emergence of the ECSA lineage of CHIKV into areas previously
affected by the Asian lineage of CHIKV [5,32,38]. While the
epidemic of CHIKV infections was propelled by the ECSA
lineage, analysis showed that the driving force behind the
emergence of the virus was its adaptation to Aedes albopictus
mosquitoes which occurred as a result of the emergence of ECSA
viruses carrying the A226V substitution in the E1 structural
protein of CHIKV [40,42]. The size of the epidemic in La
Reunion - which affected 40% of the population [34] , the
autochthonous outbreak of chikungunya fever in Italy in 2007
[45,46] and subsequently in France in 2010 [56] coupled with the
increasing spread of Aedes albopictus mosquitoes [57] all served to
fuel fear that populations previously at little or no risk of CHIKV
infection could be at risk [58].
In our analysis of eight different cell lines representing a range of
potential target cells, we found only minimal differences in the
behavior of the three different CHIKV isolates, which were two
recent isolates (CHIKV E1: A226, CHIKV E1: 226 V) and Ross
strain representing the earliest genotype of the ECSA lineage. In
both the spectrum of cells able to be infected, as well as the degree
of infection and the induction of apoptosis there were only
marginal differences between these isolates.
The two cell lines where some differences were observed in the
interaction of the three isolates were SW-982 synovial cells and
Hela cervical epithelial cells. The SW-982 cell line presented an
anomalous pattern of virus titer as compared to the other cell lines.
In cells that were susceptible to infection there was an immediate
drop in virus titer followed by de novo production at a later time
point as evidenced by an increasing titer, while the non-susceptible
U937 cell line showed no drop in titer during the initial infection.
SW-982 cells showed the drop in titer characteristic of susceptible
cells, but infectivity remained extremely low, suggesting that the
main block virus production in this cell line is not at the virus
binding/internalization step. Additionally, Ross showed the
highest level of infection of the three isolates in this cell line.
However, while arthralgia is one of the main presenting symptoms
of chikungunya infection [35,59], the direct involvement of
synovial cells in the disease pathology remains to be established.
Hela cells have previously been shown to be susceptible to
CHIKV and the level of apoptosis seen with the ECSA CHIKV
E1: 226 V isolate (about 30%) was consistent with previous reports
which utilized a similar isolate [51]. Interestingly however, both
Ross strain (which is also alanine at E1: 226) and the recent ECSA
CHIKV E1: A226 isolate showed much higher levels of infection
and apoptosis than the ECSA E1: 226 V.
The most significant difference observed between these isolates
was in their interaction with insect cells. While both the ECSA E1:
A226 and ECSA E1: 226 V isolates showed very high levels of
infectivity on day 1 p.i. the Ross strain isolate showed surprisingly
low levels (,10%) on the same day. This suggests that much of the
increased adaptation of the recent ECSA E1: 226 V lineage is also
shared by the E1: A226 isolate, at least in comparison to the Ross
strain, which suggests that the increased adaptability of the newer
isolates is the ultimate result of a longer series of changes in the
ECSA genome. In support of this, some studies have suggested
that the effect of the E1: A226V substitution is modulated by other
changes in the CHIKV genome, in particularly in the structural
E2 protein [60]. In the Aedes aegypti CCL-125 cell line, none of the
isolates showed a high level of infection, although the ECSA E1:
226 V isolate showed the highest level of infectivity, suggesting
that this isolate may also be more suited to replication in both Aedes
albopictus and Aedes aegypti as has been suggested by others [40,42].
Remarkably however, in both cell lines an almost complete
clearance of the virus was observed by day 5 for all three isolates.
While RNA interference (RNAi) in which long double stranded
RNA molecules are cleaved into small RNA effector molecules by
Dicer and which subsequently silence complimentary RNA
sequences [61] is the primary insect cell defense pathway against
invading viruses [62], this pathway is not active in C6/36 cells [63]
and as such cannot explain the mechanism by which CHIKV is
cleared from these cells. However activation of the RNAi pathway
may explain the extremely limited nature of infection seen in the
Aedes aegypti CCL-125 cells.
Table 1. Summary of susceptibility to infection and induction of apoptosis for three CHIKV isolates.
Cell line Cell type CHIKV ECSA (E1:226 V) CHIKV ECSA (E1:A226) CHIKV ECSA (ROSS)
Infection Apoptosis Infection Apoptosis Infection Apoptosis
CHME-5 Human microglial mmmm mmmm mmmm mmmm mmmm mmmm
HEK293T/17 Human embryonic kidney mmmm mmmm mmmm mmmm mmmm mmmm
Vero Monkey kidney mmmm mmm mmmm mmm mmmm mmmm
HepG2 Human hepatocellular mmmm mmmm mmmm mmmm mmmm mmmm
Hela Human cervical epithelial mm mm mmmm mmmm mmmm mmmm
MRC-5 Human lung fibroblast mmmm m ND ND ND ND
SW-982 Human synovial sarcoma 33 3mm m
U937 Human histiocytic lymphoma 33 33 33
CCL-125 Aedes aegypti m ND 3 ND 3 ND
C6/36 Aedes albopictus mmmm 3 mmmm 33 3
0%#3#20%; 21%#m#40%; 41%#mm#60%; 61%#mmm#80%; 81%#mmmm#100%; ND: Not determined.
doi:10.1371/journal.pone.0031102.t001
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infectivity or cytopathogenicity in mammalian cells. The biggest
difference between the prototype CHIKV Ross strain and
contemporary isolates was in the infectivity in insect cells,
particularly in Aedes albopictus cells, which supports the proposal
that the current spread of the ECSA is largely driven by increased
fitness of the ECSA lineage in insect vectors [42,44].
Materials and Methods
Ethics statement
The virus isolation described in the relevant section (virus
isolation and propagation) was part of a study approved by the
Mahidol University Institutional Review Board (COA.
NO. MU-IRB 2010/251.3018) and by the Ethics Review Board
of Pang Nga Hospital, Thailand. Written informed consent was
obtained.
Cells and culture conditions
The embryonic fetal human microglial cell line CHME-5 [64]
was kindly provided by Professor Pierre Talbot, Laboratory of
Neuroimmunovirology, INRS-Institute, Armand-Frappier, Cana-
da. The human lung fibroblast cell line MRC-5 [65] was kindly
provided by Assistant Professor Arunee Thitithanyanont, Micro-
biology, Faculty of Science, Mahidol University. The human
embryonic kidney cell line HEK293T/17 (ATCC Cat No. CRL-
11268) [66], the human synovial sarcoma cell line SW-982 (ATCC
Cat No. HTB-93), the human histiocytic lymphoma cell line U937
(ATCC Cat No. CRL-1593.2) [67] and the Aedes aegypti cell line
CCL-125 [50] were obtained from ATCC (American Type
Figure 4. Comparative analysis of infection and apoptosis in response to CHIKV infection. Summary of percentage infection (A) and
apoptosis induction (B) in cell lines infected with CHIKV ECSA E1:226 V (226 V), CHIKV ECSA E1: A226 (A226), Ross strain (ROSS) or mock infected
(Mock).
doi:10.1371/journal.pone.0031102.g004
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HepG2, MRC-5, Hela (ATCC Cat No. CCL-2) and SW-982 cells
were cultured at 37uC, 5% CO2 in Dulbecco’s modified Eagle’s
medium (DMEM; Gibco, Invitrogen, Carlsbad, CA) supplement-
ed with 10% heat-inactivated fetal bovine serum (FBS; Gibco,
Invitrogen) and 100 units of penicillin and 100 mg streptomycin/
ml while Vero (ATCC Cat No. CCL-81) and BHK-21 (ATCC
Cat. No. CCL-10) were supplemented with 5% FBS. U937 [67]
cells were cultured at 37uC, 5% CO2 in RPMI-1640 (Gibco,
Invitrogen) supplemented with 10% FBS and 100 units of
penicillin and 100 mg streptomycin/ml. C6/36 cells [50] were
cultured at 28uC in MEM (Gibco, Invitrogen) 10% FBS and
100 units of penicillin and 100 mg streptomycin/ml whereas CCL-
125 cells [50] were cultured in Leibovitz L-15 medium (Gibco,
Invitrogen) 20% FBS and 100 units of penicillin and 100 mg
streptomycin/ml.
Virus isolation and propagation
The CHIKV East, Central and South African (ECSA) genotype
E1: 226V was isolated from a patient in Phang Nga Province,
Thailand in 2009 and was passaged once through C6/36 cells
followed by 3 passages through passage through Vero cells. The
virus isolation was part of a study was approved by the Mahidol
University Institutional Review Board (COA. NO. MU-IRB
2010/251.3018) and by the Ethics Review Board of Pang Nga
Hospital, Thailand. Written informed consent was obtained. The
CHIKV ECSA genotype E1: A226 was a kind gift from Drs
Duane Gubler and Eng-Eong Ooi of the Emerging Infectious
Disease Program, Duke-NUS Medical School, Singapore. It was
passaged through BHK-21 cells 3 times followed by passage twice
through Vero cells. The CHIKV ECSA Ross genotype (Ross
strain, E1: A226) was passaged 5 times through Vero cells.
Virus infection
CHME-5, HEK293T/17, HepG2, MRC-5, Hela, SW-982,
U937, Vero, C6/36 and CCL-125 cells were plated into 6-well
plates and grown until cells reach approximately 80% confluency
after which cells were infected with CHIKV at a multiplicity of
infection (m.o.i.) of 1, for 2 h. After infection, fresh medium
containing serum was added to the cells and the cells were
incubated under standard conditions. Culture medium was
supplemented everyday to avoid nutrient deprivation. Infected
cells and culture medium were collected daily. At each time point,
infected cells were quantified by flow cytometry in parallel with
observation of the induction of apoptosis by FITC-conjugated
Annexin V and propidium iodide staining. The experiment was
undertaken independently in triplicate.
Flow cytometry
To analyze apoptosis, cells were collected and washed with ice-
cold PBS and were resuspended in binding buffer (BD, Franklin
Lakes, NJ), followed by double staining with the addition of
50 mg/ml FITC-conjugated Annexin V and 20 mg/ml propidium
iodide. After 15 min, the cells were analyzed by flow cytometry
(BD, FACSCalibur).
To quantify the infected cells, total cells were harvested and
blocked with 10% normal goat serum for 30 min on ice. Cells
were washed with 1% BSA follow by fixation in 4% paraformal-
dehyde at room temperature for 20 min. Subsequently cells were
permeabilized with 0.2% Triton X-100 in 1% BSA for 10 min at
room temperature. Cells were then incubated with a mouse anti-
alphavirus monoclonal antibody (Santa Cruz Biotechnology Inc.,
Santa Cruz, CA) at a dilution of 1:200 at 4uC for overnight. After
three washes with 1% BSA, cells were incubated with a FITC
conjugated goat anti-mouse IgG polyclonal antibody (KPL,
Gaithersburg, MD) at dilution of 1:20 at room temperature for
1 h. Cells were washed three times with 1% BSA and resuspended
with PBS and analyzed by flow cytometry (BD, FACSCalibur)
using the CELLQuest
TM software (BD Biosciences).
Indirect immunofluorescence microscopy
Cells were grown on cover slips and further infected with each
CHIKV at m.o.i. of 1 as previously described. At each time point,
cells were fixed with ice-cold methanol for 20 min. After washed
with PBS, cells were then permeabilized with 0.2% Triton X-100
in PBS for 10 min at room temperature before incubating with
10% normal goat serum in PBS for 1 h at room temperature.
Subsequently, cells were incubated with a mouse anti-alphavirus
monoclonal antibody (Santa Cruz Biotechnology Inc.) at a dilution
of 1:200 at 4uC for overnight. After washing, cells were incubated
with a 1:20 dilution of a FITC-conjugated goat anti-mouse IgG
polyclonal antibody (KPL, USA) and 4 mM of TO-PRO-3 iodide
(Gibco, Invitrogen) for 1 h at room temperature before the
observation under an Olympus FluoView 1000 confocal micro-
scope.
Standard plaque assay
Vero cell were plated into 6-well plate until the confluency
reached up to approximately 100 percent. Cells were inoculated
with ten-fold dilution of culture supernatant containing infectious
viruses and incubated for 2 h at 37uC with constant agitation.
Subsequently 0.8% Seakem Le agarose (Cambrex, USA) mixed
with nutrient overlay (Earle’s Balanced Salts supplemented with
0.033% (w/v) yeast extract, 0.165% lactalbumin hydrolysate, 3%
FBS) was added to each well. The plates were incubated for a
further 3 days at 37uC before 0.8% Seakem Le agarose mixed with
second nutrient overlay (Earle’s Balanced Salts supplemented with
0.063% (w/v) yeast extract, 0.315% lactalbumin hydrolysate and
0.035% (w/v) Neutral red) was added to each well. Plaques were
count after incubating the plates for a further 15–24 h at 37uC.
Each experiment was done independently in triplicate, with
duplicate assay of titer.
Supporting Information
Figure S1 CHIKV infection of HepG2 human hepatocel-
lular carcinoma cells. A. HepG2 cells were mock infected (M)
or infected with CHIKV ECSA E1: 226 V (EV) CHIKV at m.o.i.
of 1. Infected cells and culture medium were collected daily and
the medium assayed for levels of infectious CHIKV at the times
indicated by standard plaque assay on Vero cells, while cells were
assayed for infectivity and induction of apoptosis by flow
cytometry after staining with an anti-alphavirus monoclonal
antibody and FITC-conjugated Annexin V/propidium iodide
respectively. B. HepG2 cells were mock infected (M) or infected
with ECSA CHIKV E1: A226 (EA), ECSA CHIKV E1: 226 V
(EV) or Ross strain (RO) at m.o.i. of 1 and assayed for infectivity
and induction of apoptosis by flow cytometry on the days
indicated. All experiments were undertaken independently in
triplicate with duplicate analysis of virus titers. Error bars show
S.D.
(TIF)
Figure S2 CHIKV infection of Hela human cervical
carcinoma cells. A. Hela cells were mock infected (M) or
infected with CHIKV ECSA E1: 226 V (EV) CHIKV at m.o.i. of
1. Infected cells and culture medium were collected daily and the
medium assayed for levels of infectious CHIKV at the times
indicated by standard plaque assay on Vero cells, while cells were
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cytometry after staining with an anti-alphavirus monoclonal
antibody and FITC-conjugated Annexin V/propidium iodide
respectively. B. Hela cells were mock infected (M) or infected with
ECSA CHIKV E1: A226 (EA), ECSA CHIKV E1: 226 V (EV) or
Ross strain (RO) at m.o.i. of 1 and assayed for infectivity and
induction of apoptosis by flow cytometry on the days indicated. All
experiments were undertaken independently in triplicate with
duplicate analysis of virus titers. Error bars show S.D.
(TIF)
Figure S3 CHIKV infection of HEK293T/17 human fetal
kidney cells. A. HEK293T/17 cells were mock infected (M) or
infected with CHIKV ECSA E1: 226 V (EV) CHIKV at m.o.i. of
1. Infected cells and culture medium were collected daily and the
medium assayed for levels of infectious CHIKV at the times
indicated by standard plaque assay on Vero cells, while cells were
assayed for infectivity and induction of apoptosis by flow
cytometry after staining with an anti-alphavirus monoclonal
antibody and FITC-conjugated Annexin V/propidium iodide
respectively. B. HEK293T/17 cells were mock infected (M) or
infected with ECSA CHIKV E1: A226 (EA), ECSA CHIKV E1:
226 V (EV) or Ross strain (RO) at m.o.i. of 1 and assayed for
infectivity and induction of apoptosis by flow cytometry on the
days indicated. All experiments were undertaken independently in
triplicate with duplicate analysis of virus titers. Error bars show
S.D.
(TIF)
Figure S4 CHIKV infection of Vero monkey kidney
cells. A. Vero cells were mock infected (M) or infected with
CHIKV ECSA E1: 226 V (EV) at m.o.i. of 1. Infected cells and
culture medium were collected daily and the medium assayed for
levels of infectious CHIKV at the times indicated by standard
plaque assay on Vero cells, while cells were assayed for infectivity
and induction of apoptosis by flow cytometry after staining with an
anti-alphavirus monoclonal antibody and FITC-conjugated An-
nexin V/propidium iodide respectively. B. Vero cells were mock
infected (M) or infected with ECSA CHIKV E1: A226 (EA),
ECSA CHIKV E1: 226 V (EV) or Ross strain (RO) at m.o.i. of 1
and assayed for infectivity and induction of apoptosis by flow
cytometry on the days indicated. All experiments were undertaken
independently in triplicate with duplicate analysis of virus titers.
Error bars show S.D. C to F. Vero cells were mock infected (C, E)
or infected with ECSA CHIKV E1: 226 V (D, F), and on days 1
(C, D) and 2 (E, F) p.i. stained with a mouse anti-alphavirus
monoclonal antibody followed by a FITC conjugated goat anti-
mouse IgG polyclonal antibody (green). Nuclei of cells were
stained with TO-PRO-3 iodide (red). Non-contrast adjusted
merged images are shown.
(TIF)
Figure S5 CHIKV infection of SW-982 human synovial
sarcoma cells. A. SW-982 cells were mock infected (M) or
infected with CHIKV ECSA E1: 226 V (EV) at m.o.i. of 1.
Infected cells and culture medium were collected daily and the
medium assayed for levels of infectious CHIKV at the times
indicated by standard plaque assay on Vero cells, while cells were
assayed for infectivity and induction of apoptosis by flow
cytometry after staining with an anti-alphavirus monoclonal
antibody and FITC-conjugated Annexin V/propidium iodide
respectively. B. SW-982 cells were mock infected (M) or infected
with ECSA CHIKV E1: A226 (EA), ECSA CHIKV E1: 226 V
(EV) or Ross strain (RO) at m.o.i. of 1 and assayed for infectivity
and induction of apoptosis by flow cytometry on the days
indicated. All experiments were undertaken independently in
triplicate with duplicate analysis of virus titers. Error bars show
S.D. C to F. SW982 cells were mock infected (C) or infected with
ECSA CHIKV E1: 226 V (D), ECSA CHIKV E1: A226 (E) or
Ross strain (F) and on day 5 p.i. stained with a mouse anti-
alphavirus monoclonal antibody followed by a FITC conjugated
goat anti-mouse IgG polyclonal antibody (green). Nuclei of cells
were stained with TO-PRO-3 iodide (red). Non-contrast adjusted
merged images are shown.
(TIF)
Figure S6 CHIKV infection of MRC-5 human lung
fibroblast cells. MRC-5 cells were mock infected (M) or
infected with CHIKV ECSA E1: 226 V (EV) at m.o.i. of 1.
Infected cells and culture medium were collected daily and the
medium assayed for levels of infectious CHIKV at the times
indicated by standard plaque assay on Vero cells, while cells were
assayed for infectivity and induction of apoptosis by flow
cytometry after staining with an anti-alphavirus monoclonal
antibody and FITC-conjugated Annexin V/propidium iodide
respectively. All experiments were undertaken independently in
triplicate with duplicate analysis of virus titers. Error bars show
S.D.
(TIF)
Figure S7 CHIKV infection of U937 human monocytic
cells. U937 cells were mock infected (M) or infected with CHIKV
ECSA E1: 226 V (EV) at m.o.i. of 1. Infected cells and culture
medium were collected daily and the medium assayed for levels of
infectious CHIKV at the times indicated by standard plaque assay
on Vero cells, while cells were assayed for infectivity and induction
of apoptosis by flow cytometry after staining with an anti-
alphavirus monoclonal antibody and FITC-conjugated Annexin
V/propidium iodide respectively. B. U937 cells were mock
infected (M) or infected with ECSA CHIKV E1: A226 (EA),
ECSA CHIKV E1: 226 V (EV) or Ross strain (RO) at m.o.i. of 1
and assayed for infectivity and induction of apoptosis by flow
cytometry on the days indicated. All experiments were undertaken
independently in triplicate with duplicate analysis of virus titers.
Error bars show S.D.
(TIF)
Figure S8 Analysis of CHIKV infected C6/36 cells. C6/
36 cells were mock infected (A to C) or infected with CHIKV E1:
226 V (D to F), CHIKV E1: A226 (G to I) or Ross strain (J to L) at
m.o.i. of 1 and subsequently stained with a mouse anti-alphavirus
monoclonal antibody followed by a FITC conjugated goat anti-
mouse IgG polyclonal antibody (green). Nuclei of cells were
stained with TO-PRO-3 iodide (red) on days 1 (A, D, G and J), 3
(B, E, H and K) and 5 (C, F, I and L) p.i. Non-contrast adjusted
merged images are shown.
(TIF)
Figure S9 CHIKV infection of CCL-125 Aedes aegypti
cells. A. CCL-125 cells were mock infected (M) or infected with
CHIKV ECSA E1: 226 V (EV) at m.o.i. of 1. Infected cells and
culture medium were collected daily and assayed for infectivity by
flow cytometry after staining with an anti-alphavirus monoclonal
antibody.
(TIF)
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